LDN and tDCS in Fibromyalgia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 1, 2019

Study Completion Date

July 1, 2020

Conditions
Fibromyalgia
Interventions
DRUG

Low-Dose Naltrexone

4.5mg daily dose, orally, during 26 days

DEVICE

Transcranial Direct Current Stimulation

An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.

DRUG

Placebo

The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.

DEVICE

Sham Transcranial Direct Current Stimulation

Sham-tDCS stimulation consists of an active current during 30 seconds

Trial Locations (1)

92010-000

Universidade La Salle, Canoas

All Listed Sponsors
collaborator

Hospital de Clinicas de Porto Alegre

OTHER

lead

Centro Universitario La Salle

OTHER

NCT04502251 - LDN and tDCS in Fibromyalgia | Biotech Hunter | Biotech Hunter